Eli Lilly's triple-hormone drug retatrutide cut body weight by 20.8 percent over 80 weeks in adults who have both obesity and type 2 diabetes, the company reported Wednesday at the European Association for the Study of Diabetes meeting in Milan, with the full trial published the same day in The Lancet ↗01861-1). That is a large number. It is also smaller than the 28.3 percent the same drug reached, at the same top dose and over the same 80 weeks, in people who had obesity but not diabetes.
That gap is the story. Diabetes takes roughly a quarter off retatrutide's best weight-loss number, and the figure Lilly led with is the one that assumes nobody quit.
What the trial measured
Retatrutide ↗ is a single molecule that switches on three receptors at once: the ones for GLP-1 and GIP, the two gut hormones behind semaglutide ↗ and tirzepatide ↗, plus a third, glucagon, that the current drugs leave alone. The glucagon arm is meant to burn more energy on top of the appetite suppression the other two deliver.
TRIUMPH-2 randomized 1,152 adults with obesity or overweight and type 2 diabetes to weekly retatrutide at 4, 9, or 12 milligrams or to a placebo, and ran for 80 weeks across 92 centers in eight countries. Everyone started with a body mass index of 27 or higher and an A1C, the three-month blood-sugar average, between 6.5 and 10.5 percent.
Under the efficacy estimand, the analysis that measures what people lose when they actually take the drug, weight fell 12.7, 19.1, and 20.8 percent across the three doses, against 4.0 percent on placebo. A1C dropped 1.4 to 1.6 points versus 0.2. At the top dose, 59.5 percent of participants no longer met the BMI threshold for obesity, and up to 40.0 percent reached an A1C below 5.7 percent, the cutoff for a normal, non-diabetic blood-sugar level.
Which number, and whose adherence
The 20.8 percent headline is the efficacy estimand. The Lancet paper also reports a treatment-regimen estimand, which counts every randomized patient regardless of whether they stopped the drug or started a rescue medication. On that measure, the one closer to what a clinic full of real patients would see, 12-milligram retatrutide produced 18.8 percent weight loss against 5.1 percent on placebo. Two percentage points separate the two framings. Both are in the paper. Lilly's announcement leads with the higher one.
The diabetes penalty is the larger discount. People with type 2 diabetes have long lost less weight on incretin drugs than people without it, and TRIUMPH-2 now puts a number on that effect for the triple agonist. Lilly's TRIUMPH-1 trial ↗, in obesity without diabetes, reached 28.3 percent at the same 12-milligram dose over the same 80 weeks. Same drug, same program, same clock. Adding diabetes to the room took about seven and a half points off the ceiling.
The signal that scaled with dose
Retatrutide carried a side effect the single and dual agonists do not emphasize. Dysesthesia, a burning or tingling skin sensation, occurred in 4.5, 5.6, and 7.3 percent of patients across the three doses, against 0.7 percent on placebo, a rate that climbed with the dose. Discontinuation for adverse events ran 3.8, 11.6, and 7.7 percent, higher than the roughly 4 to 5 percent typical of Wegovy or tirzepatide 15 milligrams, with the 9-milligram arm oddly shedding more patients than the 12.
None of this sinks the result. A drug that normalizes blood sugar in four of ten diabetic patients and clears a fifth of their body weight is a serious entry against the strongest target in metabolic medicine, the GLP-1 receptor pipeline ↗. But the gap between 28 and 20.8, and between 20.8 and 18.8, is where the honest reading sits. Lilly plans to file retatrutide with the FDA in the first quarter of 2027.